

Special Issue

Advances in Biomarker Discovery for Cardiovascular Disease

Message from the Guest Editors

Cardiovascular disease, a disorder affecting the heart and blood vessels, is one of the leading causes of death worldwide. Multiomics, including genomics, transcriptomics, proteomics, metabolomics, etc., for biomarker discovery are unequivocally powerful tools for elucidating the molecular mechanisms underlying cardiovascular disease, which helps to unravel novel diagnostic and therapeutic biomarker candidates. This Special Issue will focus on the latest advancements in biomarker discovery for cardiovascular disease, aiming to establish earlier detection and therapy strategies. Relevant topics for this Special Issue include but are not limited to the following:

- Genomics and transcriptomics studies in cardiovascular disease;
- Proteome and peptidome analysis in cardiovascular disease;
- Post-translational modification studies in cardiovascular disease;
- Metabolomics studies in cardiovascular disease;
- Novel biomarkers discovery in cardiovascular disease;
- Identification of therapeutic targets for cardiovascular disease;
- Mass-spectrometry-based proteomics for heart and blood vessels pathophysiology;
- Development of medicines for cardiovascular disease.

Guest Editors

Dr. Qin Fu

Proteomics and Metabolomics Facility, Institute of Biotechnology,
Cornell University, Ithaca, NY 14850, USA

Dr. Haijun Liu

Transplantation Research Center (TRC), Brigham and Women's
Hospital, Harvard Medical School, Boston, MA 02115, USA

Deadline for manuscript submissions

closed (28 February 2026)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/214501

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).